Targacept Announces Pricing of Common Stock Offering
Winston-Salem, North Carolina
October 08, 2009
Targacept, Inc. (NASDAQ: TRGT) announced today that the recently announced underwritten public offering of 2,200,000 shares of its common stock has been priced at a price to the public of $21.00 per share. As previously announced, Deutsche Bank Securities will act as sole manager for the offering and Targacept has granted Deutsche Bank Securities an option to purchase an additional 320,000 shares of common stock to cover over-allotments, if any.
The offering is being made pursuant to an effective shelf registration statement that Targacept previously filed with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. This offering is being made pursuant to a prospectus supplement included as part of the registration statement. Copies of the prospectus supplement relating to this offering, when available, may be obtained by contacting Deutsche Bank Securities Inc., Deutsche Bank Securities, Prospectus Department, Harborside Financial Center, 100 Plaza One, Jersey City, New Jersey 07311-3988, telephone: 1-800-503-4611. Targacept expects the offering to close on October 13, 2009, subject to satisfaction of customary closing conditions.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has clinical-stage product candidates in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer's disease and cognitive dysfunction in schizophrenia, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline.
NNR Therapeutics (TM) is a trademark of Targacept, Inc.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 362-3087
Email: linnmich@comcast.com
Back to Newsroom